GOVERNMENT HOSPITALS & HEALTH FACILITIES CORPORATION TERRITORIAL HOSPITAL REDEVELOPMENT TEAM

4007 Estate Diamond Ruby Christiansted, VI 00821 (340)-778-6311



9048 Sugar Estate St. Thomas, VI 00802 (340)776-8311

Amendment Two (2) to the Solicitation

RFP-002-THRT-C-024 (P)- Design-Build Cleanroom Manufacturer for the JFL-North Temporary Administrative Hardened Facility November 29, 2023

I. Insert Questions and Answers:

- Your current documents are calling on professionals from many disciplines (Architect, electrical engineer, structural engineer, plumbing engineer, fire protection specialist, etc.) to work this design package, are we correct to assume that the vendor can provide a partial solution within a team, pertaining solely to the cleanroom and cleanroom related equipment and systems?
 It is expected that the vendor provide a complete solution solely to support the design and installation for the cleanroom and cleanroom related equipment systems.
- 2. HVAC Section Point III. Schedule of Work- Do you expect the new pharmacy to operate on the existing HVAC system? The new cleanroom will operate on a dedicated HVAC system independent of any existing systems.
- 3. Layout Section Point III. Schedule of Work-Pertaining to "The design for the Key Room Details" do you have preliminary lay out or at least dimensions of the requested room to better evaluate the work at hand? See Amendment One posted November 17, 2023.
- 4. Section A. Design/ Engineering Phase 1 Conceptual/Pre-Design
 - a. Architecture Regulation-Can you please confirm that there will be an architect firm involved in these discussions to cover layout, permits, ADA and hospital requirements? **Confirmed.**
 - b. Surveillance and security-Can you please confirm that there will be a dedicated security firm involved in these discussions to cover surveillance camera, telecoms and security requirements? The Owner currently has a vendor on-board who has designed and is in the process of installing surveillance camera, telecoms and security systems whom the work effort will be coordinated with.
- 5. Design/Engineering Phase 2. Architectural & Engineering Design
 - a. Structure and Hurricanes- Can you please confirm that there will be a structural firm involved in these discussions to cover a building provided over and above the cleanroom, sheltering from outside conditions? (Specifically covering the Category 5 hurricane and seismic activity requirement) **Confirmed.**
 - b. Building Information- Can you please confirm that the temporary installations for this pharmacy will be installed within an adequate building with concrete flooring, sheltered from hurricane conditions, while providing minimal connections to outside air and exhaust ducts? **Confirmed.**
 - c. Plumbing/Electricals tie-ins- Can you please confirm that there will be an electrical/plumbing firm involved in these discussions to cover their respective trades and cover tie-ins to public utility. **Confirmed.**
 - d. Energy Efficiency- Can you please confirm if there are firm energy efficiency target to achieve or regulations to meet or the considerations are solely a benefit to the overall project? There is no energy efficient target. It is expected that the selected firm will utilize "best practices" as it pertains to lighting efficiency, ie. LED lighting, as well as efficient HVAC systems.







GOVERNMENT HOSPITALS & HEALTH FACILITIES CORPORATION TERRITORIAL HOSPITAL REDEVELOPMENT TEAM

4007 Estate Diamond Ruby Christiansted, VI 00821 (340)-778-6311



9048 Sugar Estate St. Thomas, VI 00802 (340)776-8311

- 7. Exhaust Connections Can you please confirm who will be responsible for managing the exhausted content of the USP800 room, other than the awarded vendor (Stack, fans and dispersion analysis as applicable)? The selected vendor is responsible for managing the exhaust content of the USP800 room and will be responsible for submitting a sample dispersion analysis in comparison with industry standards as applicable. See attached
- 8. HVAC:
 - a. Temperature and humidity requirement within the rooms? $660F \pm 30F$, 30% to 60% HR? Yes.
 - b. Temperature and humidity of the surrounding space around the project? 70oF to 75oF, 20% to 60% HR? **Outside air temperatures can range from 70oF up to 95oF.**
 - c. Is there a chilled water and hot water plant in the building that we must use for our cooling and heating capacity? **No**
 - d. How much free space do we have over the cleanrooms? The proposed floor plan is 450 SQFT. The proposed interior height is 16'.
 - e. If no chilled water loop is available on site, do you need rooftop package unit or split unit with the AHUs inside the building on top of our cleanroom? No chill water loop available thus you will need a dedicated AHU.
 - f. Do you need a dedicated AHU for each suite to avoid any risk of cross-contamination between the suites? **There is only one dedicated suite proposed.**
 - g. Do you need all the heating and/or humidification to be on natural gas or are electrical ok? All electric.
 - h. Any need for redundancy on your HVAC equipment? No.
- 9. Can the site plans /schematics/layouts be shared with the vendors? See Amendment One posted November 17, 2023.
- 10. Is the physical space shelled or does it need to be built? It will be shelled.
- 11. Besides the 4 hoods that are being relocated, what other equipment will need to be moved? **None.**
- 12. Does the turnkey request include all FF&E? Yes
- 13. Is the drug management hardware and software a part of the scope? No
- 14. What is the timeline for the project? Not to exceed six (6) months after issuance of NTP.

ALL OTHER TERMS AND CONDITIONS REMAIN UNCHANGED. A COPY OF THIS AMMENDMENT MUST BE RETURNED WITH YOUR BID



"Together We Are Stronger"



Printed on: Wed Nov 22 2023, 13:03:24 pm Printed by: Laura Forbes Status: Currently Official on 22-Nov-2023 Official Date: Official as of 01-Jul-2020 Document Type: GENERAL CHAPTER Docld: GUID-5D76173F-5CB6-47B8-815E-7C275A916085_7_en-US DOI: https://doi.org/10.31003/USPNF_M7808_07_01 DOI Ref: ifp62 Do not distribute © 2023 USPC

$\langle 800 \rangle$ HAZARDOUS DRUGS—HANDLING IN HEALTHCARE SETTINGS

To view the Notice from the Expert Committee that posted in conjunction with this accelerated revision, please click https://www.uspnf.com/rb/gc-800-20200626.

1. INTRODUCTION AND SCOPE

This chapter describes practice and quality standards for handling hazardous drugs (HDs) to promote patient safety, worker safety, and environmental protection. Handling HDs includes, but is not limited to, the receipt, storage, compounding, dispensing, administration, and disposal of sterile and nonsterile products and preparations.

This chapter applies to all healthcare personnel who handle HD preparations and all entities that store, prepare, transport, or administer HDs (e.g., pharmacies, hospitals and other healthcare institutions, patient treatment clinics, physicians' practice facilities, or veterinarians' offices). Personnel who may potentially be exposed to HDs include, but are not limited to: pharmacists, pharmacy technicians, nurses, physicians, physician assistants, home healthcare workers, veterinarians, and veterinary technicians.

Entities that handle HDs must incorporate the standards in this chapter into their occupational safety plan. The entity's health and safety management system must, at a minimum, include:

- A list of HDs
- Facility and engineering controls
- Competent personnel
- Safe work practices
- Proper use of appropriate Personal Protective Equipment (PPE)
- Policies for HD waste segregation and disposal
- The chapter is organized into the following main sections:
 - 1. Introduction and Scope
 - 2. List of Hazardous Drugs
 - 3. <u>Types of Exposure</u>
 - 4. <u>Responsibilities of Personnel Handling Hazardous Drugs</u>
 - 5. Facilities and Engineering Controls
 - 6. Environmental Quality and Control
 - 7. <u>Personal Protective Equipment</u>
 - 8. Hazard Communication Program
 - 9. Personnel Training
- 10. <u>Receiving</u>
- 11. Labeling, Packaging, Transport, and Disposal
- 12. Dispensing Final Dosage Forms
- 13. Compounding
- 14. Administering
- 15. Deactivating, Decontaminating, Cleaning, and Disinfecting
- 16. <u>Spill Control</u>
- 17. Documentation and Standard Operating Procedures
- 18. Medical Surveillance

<u>Glossary</u>

<u>Appendices</u>

<u>Appendix 1: Acronyms</u> <u>Appendix 2: Examples of Designs for Hazardous Drug Compounding Areas</u>

Change to read:

2. LIST OF HAZARDOUS DRUGS

The National Institute for Occupational Safety and Health (NIOSH) maintains a list of antineoplastic and other HDs used in healthcare. For the purposes of this chapter, the term antineoplastic only refers to antineoplastic drugs included in Table 1 of the most current NIOSH List. (RB 1-Jul-2020) An entity must maintain a list of HDs, which must include any items on the current NIOSH list that the entity handles. The entity's list must be reviewed at least every 12 months. Whenever a new agent or dosage form is used, it should be reviewed against the entity's list.

The NIOSH list of antineoplastic and other HDs provides the criteria used to identify HDs. These criteria must be used to identify HDs that enter the market after the most recent version of the NIOSH list, or that the entity handles as an investigational drug. If the information available on a drug is deemed insufficient to make an informed decision, consider the drug hazardous until more information is available.

Box 1: Containment Requirements

- Drugs on the NIOSH list that must follow the requirements in this chapter include:
 - Any HD API
 - Any antineoplastic requiring HD manipulation
- Drugs on the NIOSH list that do not have to follow all the containment requirements of this chapter if an assessment of risk is performed and implemented include:
 - Final dosage forms of compounded HD preparations and conventionally manufactured HD products, including antineoplastic dosage forms that do not require any further manipulation other than counting or repackaging (unless required by the manufacturer)
- For dosage forms of other HDs on the NIOSH list, the entity may perform an assessment of risk to determine alternative containment strategies and/work practices

Some dosage forms of drugs defined as hazardous may not pose a significant risk of direct occupational exposure because of their dosage formulation (e.g., tablets or capsules—solid, intact medications that are administered to patients without modifying the formulation). However, dust from tablets and capsules may present a risk of exposure by skin contact and/or inhalation. An assessment of risk may be performed for these dosage forms to determine alternative containment strategies and/or work practices. If an assessment of risk is not performed, all HDs must be handled with all containment strategies defined in this chapter.

The assessment of risk must, at a minimum, consider the following:

- Type of HD (e.g., antineoplastic, non-antineoplastic, reproductive risk only)
- Dosage form
- Risk of exposure
- Packaging
- Manipulation

If an assessment of risk approach is taken, the entity must document what alternative containment strategies and/or work practices are being employed for specific dosage forms to minimize occupational exposure. If used, the assessment of risk must be reviewed at least every 12 months and the review documented.

3. TYPES OF EXPOSURE

Routes of unintentional entry of HDs into the body include dermal and mucosal absorption, inhalation, injection, and ingestion (e.g., contaminated foodstuffs, spills, or mouth contact with contaminated hands). Containers of HDs have been shown to be contaminated upon receipt. Both clinical and nonclinical personnel may be exposed to HDs when they handle HDs or touch contaminated surfaces. <u>Table 1</u> lists examples of potential routes of exposure based on activity.

Table 1. Examples of Potential Opportunities of Exposure Based on Activity

Activity Potential Opportunity of Exposure			
Receipt	Contacting HD residues present on drug containers, inc dosage units, outer containers, work surfaces, or floors		

Activity	Potential Opportunity of Exposure		
Dispensing	Counting or repackaging tablets and capsules		
Compounding and other	 Crushing or splitting tablets or opening capsules Pouring oral or topical liquids from one container to another Weighing or mixing components Constituting or reconstituting powdered or lyophilized HDs Withdrawing or diluting injectable HDs from parenteral containers Expelling air or HDs from syringes Contacting HD residue present on PPE or other garments Deactivating, decontaminating, cleaning, and disinfecting areas contaminated with or suspected to be contaminated with HDs Maintenance activities for potentially contaminated equip- 		
manipulations	ment and devices		
Administration	 Generating aerosols during administration of HDs by various routes (e.g., injection, irrigation, oral, inhalation, or topical application) Performing certain specialized procedures (e.g., intraoperative intraperitoneal injection or bladder instillation) Priming an IV administration set 		
Patient-care activities	 Handling body fluids (e.g., urine, feces, sweat, or vomit) or body-fluid-contaminated clothing, dressings, linens, and other materials 		
Spills	Spill generation, management, and disposal		
Transport	Moving HDs within a healthcare setting		
Waste	Collection and disposal of hazardous waste and trace con- taminated waste		

4. RESPONSIBILITIES OF PERSONNEL HANDLING HAZARDOUS DRUGS

Each entity must have a designated person who is qualified and trained to be responsible for developing and implementing appropriate procedures; overseeing entity compliance with this chapter and other applicable laws, regulations, and standards; ensuring competency of personnel; and ensuring environmental control of the storage and compounding areas. The designated person must thoroughly understand the rationale for risk-prevention policies, risks to themselves and others, risks of non-compliance that may compromise safety, and the responsibility to report potentially hazardous situations to the management team. The designated person must also be responsible for the oversight of monitoring the facility and maintaining reports of testing/sampling performed in facilities, and acting on the results.

All personnel who handle HDs are responsible for understanding the fundamental practices and precautions and for continually evaluating these procedures and the quality of final HDs to prevent harm to patients, minimize exposure to personnel, and minimize contamination of the work and patient-care environment.

5. FACILITIES AND ENGINEERING CONTROLS

HDs must be handled under conditions that promote patient safety, worker safety, and environmental protection. Signs designating the hazard must be prominently displayed before the entrance to the HD handling areas. Access to areas where HDs are handled must be restricted to authorized personnel to protect persons not involved in HD handling. HD handling areas must be located away from breakrooms and refreshment areas for personnel, patients, or visitors to reduce risk of exposure.

Designated areas must be available for:

- Receipt and unpacking
- Storage of HDs

- Nonsterile HD compounding (if performed by the entity)
- Sterile HD compounding (if performed by the entity)

Certain areas are required to have negative pressure from surrounding areas to contain HDs and minimize risk of exposure. Consideration should be given to uninterrupted power sources (UPS) for the ventilation systems to maintain negative pressure in the event of power loss.

5.1 Receipt

Antineoplastic HDs and all HD APIs must be unpacked (i.e., removal from external shipping containers) in an area that is neutral/normal or negative pressure relative to the surrounding areas. HDs must not be unpacked from their external shipping containers in sterile compounding areas or in positive pressure areas.

5.2 Storage

HDs must be stored in a manner that prevents spillage or breakage if the container falls. Do not store HDs on the floor. In areas prone to specific types of natural disasters (e.g., earthquakes) the manner of storage must meet applicable safety precautions, such as secure shelves with raised front lips.

Antineoplastic HDs requiring manipulation other than counting or repackaging of final dosage forms and any HD API must be stored separately from non-HDs in a manner that prevents contamination and personnel exposure. These HDs must be stored in an externally ventilated, negative-pressure room with at least 12 air changes per hour (ACPH). Non-antineoplastic, reproductive risk only, and final dosage forms of antineoplastic HDs may be stored with other inventory if permitted by entity policy.

Sterile and nonsterile HDs may be stored together, but HDs used for nonsterile compounding should not be stored in areas designated for sterile compounding to minimize traffic into the sterile compounding area.

Refrigerated antineoplastic HDs must be stored in a dedicated refrigerator in a negative pressure area with at least 12 ACPH [e.g., storage room, buffer room, or containment segregated compounding area (C-SCA)]. If a refrigerator is placed in a negative pressure buffer room, an exhaust located adjacent to the refrigerator's compressor and behind the refrigerator should be considered.

5.3 Compounding

Engineering controls are required to protect the preparation from cross-contamination and microbial contamination (if preparation is intended to be sterile) during all phases of the compounding process. Engineering controls for containment are divided into three categories representing primary, secondary, and supplementary levels of control. A containment primary engineering control (C-PEC) is a ventilated device designed to minimize worker and environmental HD exposure when directly handling HDs. The containment secondary engineering control (C-SEC) is the room in which the C-PEC is placed. Supplemental engineering controls [e.g., closed-system drug-transfer device (CSTD)] are adjunct controls to offer additional levels of protection. <u>Appendix 2</u> provides examples for designs of HD compounding areas.

Sterile and nonsterile HDs must be compounded within a C-PEC located in a C-SEC. The C-SEC used for sterile and nonsterile compounding must:

- · Be externally vented
- · Be physically separated (i.e., a different room from other preparation areas)
- Have an appropriate air exchange (e.g., ACPH)
- Have a negative pressure between 0.01 and 0.03 inches of water column relative to all adjacent areas

The C-PEC must operate continuously if it supplies some or all of the negative pressure in the C-SEC or if it is used for sterile compounding. If there is any loss of power to the C-PEC, or if repair or moving occurs, all activities occurring in the C-PEC must be suspended immediately. If necessary, protect the unit by covering it appropriately per the manufacturer's recommendations. Once the C-PEC can be powered on, decontaminate, clean, and disinfect (if used for sterile compounding) all surfaces and wait the manufacturer-specified recovery time before resuming compounding.

A sink must be available for hand washing. An eyewash station and/or other emergency or safety precautions that meet applicable laws and regulations must be readily available. Care must be taken to locate water sources and drains in areas where their presence will not interfere with required ISO classifications. Water sources and drains must be located at least 1 meter away from the C-PEC.

For entities that compound both nonsterile and sterile HDs, the respective C-PECs must be placed in separate rooms, unless those C-PECs used for nonsterile compounding are sufficiently effective that the room can continuously maintain ISO 7 classification throughout the nonsterile compounding activity. If the C-PECs used for sterile and nonsterile compounding are placed in the same room, they must be placed at least 1 meter apart and particle-generating activity must not be performed when sterile compounding is in process.

5.3.1 NONSTERILE COMPOUNDING

In addition to this chapter, nonsterile compounding must follow standards in <u>Pharmaceutical Compounding–Nonsterile Preparations (795)</u>. A C-PEC is not required if manipulations are limited to handling of final dosage forms (e.g., counting or repackaging of tablets and capsu is at do not produce particles, aerosols, or gasses.

The C-PECs used for manipulation of nonsterile HDs must be either externally vented (preferred) or have redundant-HEPA filters in series. Nonsterile HD compounding must be performed in a C-PEC that provides personnel and environmental protection, such as a Class I Biological Safety Cabinet (BSC) or Containment Ventilated Enclosure (CVE). A Class II BSC or a compounding aseptic containment isolator (CACI) may also be used. For occasional nonsterile HD compounding, a C-PEC used for sterile compounding (e.g., Class II BSC or CACI) may be used but must be decontaminated, cleaned, and disinfected before resuming sterile compounding in that C-PEC. A C-PEC used only for nonsterile compounding does not require unidirectional airflow because the critical environment does not need to be ISO classified.

The C-PEC must be placed in a C-SEC that has at least 12 ACPH. <u>Table 2</u> summarizes the engineering controls required for nonsterile HD compounding.

Due to the difficulty of cleaning HD contamination, surfaces of ceilings, walls, floors, fixtures, shelving, counters, and cabinets in the nonsterile compounding area must be smooth, impervious, free from cracks and crevices, and non-shedding.

Table 2. Engineering Controls for Nonsterile HD Compounding

C-PEC	C-SEC Requirements	
 Externally vented (preferred) or redundant–HEPA filtered in series Examples: CVE, Class I or II BSC, CACI 	 Externally vented 12 ACPH Negative pressure between 0.01 and 0.03 inches of water column relative to adjacent areas 	

5.3.2 STERILE COMPOUNDING

In addition to this chapter, sterile compounding must follow standards in <u>(797)</u>.

All C-PECs used for manipulation of sterile HDs must be externally vented. Sterile HD compounding must be performed in a C-PEC that provides an ISO Class 5 or better air quality, such as a Class II or III BSC or CACI. Class II BSC types A2, B1, or B2 are acceptable. For most known HDs, type A2 cabinets offer a simple and reliable integration with the ventilation and pressurization requirements of the C-SEC. Class II type B2 BSCs are typically reserved for use with volatile components. *Appendix 3* describes the different types of BSCs.

A laminar airflow workbench (LAFW) or compounding aseptic isolator (CAI) must not be used for the compounding of an antineoplastic HD. A BSC or CACI used for the preparation of HDs must not be used for the preparation of a non-HD unless the non-HD preparation is placed into a protective outer wrapper during removal from the C-PEC and is labeled to require PPE handling precautions.

The C-PEC must be located in a C-SEC, which may either be an ISO Class 7 buffer room with an ISO Class 7 ante-room (preferred) or an unclassified containment segregated compounding area (C-SCA). If the C-PEC is placed in a C-SCA, the beyond-use date (BUD) of all compounded sterile preparations (CSPs) prepared must be limited as described in <u>(797)</u> for CSPs prepared in a segregated compounding area. <u>Table 3</u> summarizes the engineering controls required for sterile HD compounding.

Table 3. Engineering Controls for Sterile HD Compounding

Configuration	C-PEC C-SEC		Maximum BUD	
ISO Class 7 buffer room with an ISO Class 7 ante-room	 Externally vented Examples: Class II BSC or CACI 	 Externally vented 30 ACPH Negative pressure be- tween 0.01 and 0.03 inches of water column relative to adjacent areas 	As described in <u>(797)</u>	
Unclassified C-SCA	 Externally vented Examples: Class II BSC or CACI 	 Externally vented 12 ACPH Negative pressure be- tween 0.01 and 0.03 inches of water column relative to adjacent areas 	As described in <u>(797)</u> for CSPs prepared in a segregated compounding area	

ISO Class 7 buffer room with an ISO class 7 ante-room: The C-PEC is placed in an ISO Class 7 buffer room that has fixed walls, HEPA-filtered supply air, a negative pressure between 0.01 and 0.03 inches of water column relative to all adjacent areas and a minimum of 30 ACPH

The buffer room must be externally vented. Because the room through which entry into the HD buffer room (e.g., ante-room or non-H or room) plays an important role in terms of total contamination control, the following is required:

• Minimum of 30 ACPH of HEPA-filtered supply air

- · Maintain a positive pressure of at least 0.02 inches of water column relative to all adjacent unclassified areas
- · Maintain an air quality of ISO Class 7 or better

An ISO Class 7 ante-room with fixed walls is necessary to provide inward air migration of equal cleanliness classified air into the negative pressure buffer room to contain any airborne HD. A hand-washing sink must be placed in the ante-room at least 1 meter from the entrance to the HD buffer room to avoid contamination migration into the negative pressure HD buffer room.

Although not a recommended facility design, if the negative-pressure HD buffer room is entered though the positive-pressure non-HD buffer room, the following is also required:

- A line of demarcation must be defined within the negative-pressure buffer room for donning and doffing PPE
- A method to transport HDs, HD CSPs, and HD waste into and out of the negative pressure buffer room to minimize the spread of HD contamination. This may be accomplished by use of a pass-through chamber between the negative-pressure buffer area and adjacent space. The pass-through chamber must be included in the facility's certification to ensure that particles are not compromising the air quality of the negative-pressure buffer room. A refrigerator pass-through must not be used. Other methods of containment (such as sealed containers) may be used.

HD CSPs prepared in an ISO Class 7 buffer room with an ISO Class 7 ante-room may use the BUDs described in (797), based on the categories of CSP, sterility testing, and storage temperature.

Containment segregated compounding area (C-SCA): The C-PEC is placed in an unclassified C-SCA that has fixed walls, a negative pressure between 0.01 and 0.03 inches of water column relative to all adjacent areas, and a minimum of 12 ACPH. The C-SCA must be externally vented. A hand-washing sink must be placed at least 1 meter from C-PEC and may be either inside the C-SCA or directly outside the C-SCA.

Only low- and medium-risk HD CSPs may be prepared in a C-SCA. HD CSPs prepared in the C-SCA must not exceed the BUDs described in <u>(797)</u> for CSPs prepared in a segregated compounding area.

5.4 Containment Supplemental Engineering Controls

Containment supplemental engineering controls, such as CSTDs, provide adjunct controls to offer an additional level of protection during compounding or administration. Some CSTDs have been shown to limit the potential of generating aerosols during compounding. However, there is no certainty that all CSTDs will perform adequately. Until a published universal performance standard for evaluation of CSTD containment is available, users should carefully evaluate the performance claims associated with available CSTDs based on independent, peer-reviewed studies and demonstrated contamination reduction.

A CSTD must not be used as a substitute for a C-PEC when compounding. CSTDs should be used when compounding HDs when the dosage form allows. CSTDs must be used when administering antineoplastic HDs when the dosage form allows. CSTDs known to be physically or chemically incompatible with a specific HD must not be used for that HD.

6. ENVIRONMENTAL QUALITY AND CONTROL

Environmental wipe sampling for HD surface residue should be performed routinely (e.g., initially as a benchmark and at least every 6 months, or more often as needed, to verify containment). Surface wipe sampling should include:

- · Interior of the C-PEC and equipment contained in it
- Pass-through chambers
- · Surfaces in staging or work areas near the C-PEC
- Areas adjacent to C-PECs (e.g., floors directly under C-PEC, staging, and dispensing area)
- · Areas immediately outside the HD buffer room or the C-SCA
- Patient administration areas

There are currently no studies demonstrating the effectiveness of a specific number or size of wipe samples in determining levels of HD contamination. Wipe sampling kits should be verified before use to ensure the method and reagent used have been tested to recover a specific percentage of known marker drugs from various surface types found in the sampled area. There are currently no certifying agencies for vendors of wipe sample kits.

There is currently no standard for acceptable limits for HD surface contamination. Common marker HDs that can be assayed include cyclophosphamide, ifosfamide, methotrexate, fluorouracil, and platinum-containing drugs. An example of measurable contamination would be cyclophosphamide levels >1.00 ng/cm², which were shown in some studies to result in uptake of the drug in exposed workers. If any measurable contamination is found, the designated person must identify, document, and contain the cause of contamination. Such action may include reevaluating work practices, re-training personnel, performing thorough deactivation, decontamination, cleaning, and improving engineering controls. Repeat the wipe sampling to validate that the deactivation/decontamination and cleaning steps have been effective.

7. PERSONAL PROTECTIVE EQUIPMENT

Personal Protective Equipment (PPE) provides worker protection to reduce exposure to HD aerosols and residues. Additional PPE ma required to handle the HDs outside of a C-PEC, such as treating a patient or cleaning a spill. The NIOSH list of antineoplastic and other H

provides general guidance on PPE for possible scenarios that may be encountered in healthcare settings. Disposable PPE must not be re-used. Reusable PPE must be decontaminated and cleaned after use.

Gowns, head, hair, shoe covers, and two pairs of chemotherapy gloves are required for compounding sterile and nonsterile HDs. Two pairs of chemotherapy gloves are required for administering injectable antineoplastic HDs. Gowns shown to resist permeability by HDs are required when administering injectable antineoplastic HDs. For all other activities, the entity's SOP must describe the appropriate PPE to be worn based on its occupational safety plan and assessment of risk (if used). The entity must develop SOPs for PPE based on the risk of exposure (see *Types of Exposure*) and activities performed.

Appropriate PPE must be worn when handling HDs including during:

- Receipt
- Storage
- Transport
- Compounding (sterile and nonsterile)
- Administration
- · Deactivation/decontamination, cleaning, and disinfecting
- Spill control
- Waste disposal

7.1 Gloves

When chemotherapy gloves are required, they must meet American Society for Testing and Materials (ASTM) standard D6978 (or its successor). Chemotherapy gloves should be worn for handling all HDs including non-antineoplastics and for reproductive risk only HDs. Chemotherapy gloves must be powder-free because powder can contaminate the work area and can adsorb and retain HDs. Gloves must be inspected for physical defects before use. Do not use gloves with pin holes or weak spots.

When used for sterile compounding, the outer chemotherapy gloves must be sterile. Chemotherapy gloves should be changed every 30 minutes unless otherwise recommended by the manufacturer's documentation and must be changed when torn, punctured, or contaminated. Hands must be washed with soap and water after removing gloves.

7.2 Gowns

When gowns are required, they must be disposable and shown to resist permeability by HDs. Gowns must be selected based on the HDs handled. Disposable gowns made of polyethylene-coated polypropylene or other laminate materials offer better protection than those made of uncoated materials. Gowns must close in the back (i.e., no open front), be long sleeved, and have closed cuffs that are elastic or knit. Gowns must not have seams or closures that could allow HDs to pass through.

Cloth laboratory coats, surgical scrubs, isolation gowns, or other absorbent materials are not appropriate protective outerwear when handling HDs because they permit the permeation of HDs and can hold spilled drugs against the skin, thereby increasing exposure. Clothing may also retain HD residue from contact, and may transfer to other healthcare workers or various surfaces. Washing of non-disposable clothing contaminated with HD residue should only be done according to facility policy as drug residue may be transferred to other clothing. Potentially contaminated clothing must not be taken home under any circumstances.

Gowns must be changed per the manufacturer's information for permeation of the gown. If no permeation information is available for the gowns used, change them every 2–3 hours or immediately after a spill or splash. Gowns worn in HD handling areas must not be worn to other areas in order to avoid spreading HD contamination and exposing other healthcare workers.

7.3 Head, Hair, Shoe, and Sleeve Covers

Head and hair covers (including beard and moustache, if applicable), shoe covers, and sleeve covers provide protection from contact with HD residue. When compounding HDs, a second pair of shoe covers must be donned before entering the C-SEC and doffed when exiting the C-SEC. Shoe covers worn in HD handling areas must not be worn to other areas to avoid spreading HD contamination and exposing other healthcare workers.

Disposable sleeve covers may be used to protect areas of the arm that may come in contact with HDs. Disposable sleeve covers made of polyethylene-coated polypropylene or other laminate materials offer better protection than those made of uncoated materials.

7.4 Eye and Face Protection

Many HDs are irritating to the eyes and mucous membranes. Appropriate eye and face protection must be worn when there is a risk for spills or splashes of HDs or HD waste materials when working outside of a C-PEC (e.g., administration in the surgical suite, working at or above eye level, or cleaning a spill). A full-facepiece respirator provides eye and face protection. Goggles must be used when eye protection is needed. Eye glasses alone or safety glasses with side shields do not protect the eyes adequately from splashes. Face shields in combination with go provide a full range of protection against splashes to the face and eyes. Face shields alone do not provide full eye and face protection.

7.5 Respiratory Protection

Personnel who are unpacking HDs that are not contained in plastic should wear an elastomeric half-mask with a multi-gas cartridge and P100-filter until assessment of the packaging integrity can be made to ensure no breakage or spillage occurred during transport. If the type of drug can be better defined, a more targeted cartridge can be used.

Surgical masks do not provide respiratory protection from drug exposure and must not be used when respiratory protection from HD exposure is required. A surgical N95 respirator provides the respiratory protection of an N95 respirator, and like a surgical mask, provides a barrier to splashes, droplets, and sprays around the nose and mouth.

For most activities requiring respiratory protection, a fit-tested NIOSH-certified N95 or more protective respirator is sufficient to protect against airborne particles. However, N95 respirators offer no protection against gases and vapors and little protection against direct liquid splashes (see the Centers for Disease Control and Prevention's (CDC's) Respirator Trusted-Source Information).

Fit test the respirator and train workers to use respiratory protection. Follow all requirements in the Occupational Safety and Health Administration (OSHA) respiratory protection standard (29 CFR 1910.134). An appropriate full-facepiece, chemical cartridge-type respirator or powered air-purifying respirator (PAPR) should be worn when there is a risk of respiratory exposure to HDs, including when:

- Attending to HD spills larger than what can be contained with a spill kit
- Deactivating, decontaminating, and cleaning underneath the work surface of a C-PEC
- · There is a known or suspected airborne exposure to powders or vapors

7.6 Disposal of Used Personal Protective Equipment

Consider all PPE worn when handling HDs to be contaminated with, at minimum, trace quantities of HDs. PPE must be placed in an appropriate waste container and further disposed of per local, state, and federal regulations. PPE worn during compounding should be disposed of in the proper waste container before leaving the C-SEC. Chemotherapy gloves and sleeve covers (if used) worn during compounding must be carefully removed and discarded immediately into a waste container approved for trace contaminated waste inside the C-PEC or contained in a sealable bag for discarding outside the C-PEC.

8. HAZARD COMMUNICATION PROGRAM

Entities are required to establish policies and procedures that ensure worker safety during all aspects of HD handling. The entity must develop SOPs to ensure effective training regarding proper labeling, transport, storage, and disposal of the HDs and use of Safety Data Sheets (SDS), based on the Globally Harmonized System of Classification and Labeling of Chemicals (GHS).

Elements of the hazard communication program plan must include:

- · A written plan that describes how the standard will be implemented
- All containers of hazardous chemicals must be labeled, tagged, or marked with the identity of the material and appropriate hazard
 warnings
- Entities must have an SDS for each hazardous chemical they use (29 CFR 1910.1200)
- Entities must ensure that the SDSs for each hazardous chemical used are readily accessible to personnel during each work shift and when they are in their work areas
- Personnel who may be exposed to hazardous chemicals when working must be provided information and training before the initial
 assignment to work with a hazardous chemical, and also whenever the hazard changes
- · Personnel of reproductive capability must confirm in writing that they understand the risks of handling HDs

9. PERSONNEL TRAINING

All personnel who handle HDs must be trained based on their job functions (e.g., in the receipt, storage, compounding, repackaging, dispensing, administrating, and disposing of HDs). Training must occur before the employee independently handles HDs. The effectiveness of training for HD handling competencies must be demonstrated by each employee. Personnel competency must be reassessed at least every 12 months. Personnel must be trained prior to the introduction of a new HD or new equipment and prior to a new or significant change in process or SOP. All training and competency assessment must be documented.

The training must include at least the following:

- Overview of entity's list of HDs and their risks
- · Review of the entity's SOPs related to handling of HDs
- Proper use of PPE
- · Proper use of equipment and devices (e.g., engineering controls)
- · Response to known or suspected HD exposure
- Spill management
- · Proper disposal of HDs and trace-contaminated materials

10. RECEIVING

The entity must establish SOPs for receiving HDs. HDs should be received from the supplier in impervious plastic to segregate them from other drugs and to allow for safety in the receiving and internal transfer process. HDs must be delivered to the HD storage area immediately after unpacking.

PPE, including chemotherapy gloves, must be worn when unpacking HDs (see *Personal Protective Equipment*). A spill kit must be accessible in the receiving area.

The entity must enforce policies that include a tiered approach, starting with visual examination of the shipping container for signs of damage or breakage (e.g., visible stains from leakage, sounds of broken glass). <u>Table 4</u> summarizes the steps for receiving and handling of damaged shipping containers.

If the shipping container appears damaged	 Seal container without opening and contact the supplier If the unopened package is to be returned to the supplier, enclose the package in an impervious container and label the outer container "Hazardous" If the supplier declines return, dispose of as hazardous waste
If a damaged shipping container must be opened	 Seal the container in plastic or an impervious container Transport it to a C-PEC and place on a plastic-backed preparation mat Open the package and remove undamaged items Wipe the outside of the undamaged items with a disposable wipe Enclose the damaged item(s) in an impervious container and label the outer container "Hazardous" If the supplier declines return, dispose of as hazardous waste Deactivate, decontaminate, and clean the C-PEC (see <i>Deactivating, Decontaminating, Cleaning, and Disinfecting</i>) and discard the mat and cleaning disposables as hazardous waste

Table 4. Summary of Requirements for Receiving and Handling Damaged HD Shipping Containers

When opening damaged shipping containers, they should preferably be transported to a C-PEC designated for nonsterile compounding. If a C-PEC designated for sterile compounding is the only one available, it must be disinfected after the decontamination, deactivation, and cleaning step before returning to any sterile compounding activity.

Damaged packages or shipping cartons must be considered spills that must be reported to the designated person and managed according to the entity's SOPs. Segregate HDs waiting to be returned to the supplier in a designated negative pressure area. Clean-up must comply with established SOPs.

11. LABELING, PACKAGING, TRANSPORT AND DISPOSAL

The entity must establish SOPs for the labeling, packaging, transport, and disposal of HDs. The SOPs must address prevention of accidental exposures or spills, personnel training on response to exposure, and use of a spill kit. Examples of special exposure-reducing strategies include small-bore connectors (such as Luer Lock) and syringes, syringe caps, CSTDs, the capping of container ports, sealed impervious plastic bags, impact-resistant and/or water-tight containers, and cautionary labeling.

11.1 Labeling

HDs identified by the entity as requiring special HD handling precautions must be clearly labeled at all times during their transport. Personnel must ensure that the labeling processes for compounded preparations do not introduce contamination into the non-HD handling areas.

11.2 Packaging

Personnel must select and use packaging containers and materials that will maintain physical integrity, stability, and sterility (if needed) of the HDs during transport. Packaging materials must protect the HD from damage, leakage, contamination, and degradation, while protecting healthcare workers who transport HDs. The entity must have written SOPs to describe appropriate shipping containers and insulating m s, based on information from product specifications, vendors, and mode of transport.

11.3 Transport

HDs that need to be transported must be labeled, stored, and handled in accordance with applicable federal, state, and local regulations. HDs must be transported in containers that minimize the risk of breakage or leakage. Pneumatic tubes must not be used to transport any liquid HDs or any antineoplastic HDs because of the potential for breakage and contamination.

When shipping HDs to locations outside the entity, the entity must consult the Transport Information on the SDS. The entity must ensure that labels and accessory labeling for the HDs include storage instructions, disposal instructions, and HD category information in a format that is consistent with the carrier's policies.

11.4 Disposal

All personnel who perform routine custodial waste removal and cleaning activities in HD handling areas must be trained in appropriate procedures to protect themselves and the environment to prevent HD contamination. Disposal of all HD waste, including, but not limited to, unused HDs and trace-contaminated PPE and other materials, must comply with all applicable federal, state, and local regulations.

12. DISPENSING FINAL DOSAGE FORMS

HDs that do not require any further manipulation, other than counting or repackaging of final dosage forms, may be prepared for dispensing without any further requirements for containment unless required by the manufacturer or if visual indicators of HD exposure hazards are present (e.g., HD dust or leakage).

Counting or repackaging of HDs must be done carefully. Clean equipment should be dedicated for use with HDs and should be decontaminated after every use. Tablet and capsule forms of antineoplastic HDs must not be placed in automated counting or packaging machines, which subject them to stress and may create powdered contaminants.

13. COMPOUNDING

Entities and personnel involved in compounding HDs must be compliant with the appropriate USP standards for compounding including (795) and (797). Compounding must be done in proper engineering controls as described in *Compounding*. When compounding HD preparations in a C-PEC, a plastic-backed preparation mat should be placed on the work surface of the C-PEC. The mat should be changed immediately if a spill occurs and regularly during use, and should be discarded at the end of the daily compounding activity. Disposable or clean equipment for compounding (such as mortars and pestles, and spatulas) must be dedicated for use with HDs.

Bulk containers of liquid and API HD must be handled carefully to avoid spills. If used, APIs or other powdered HDs must be handled in a C-PEC to protect against occupational exposure, especially during particle-generating activities (such as crushing tablets, opening capsules, and weighing powder).

14. ADMINISTERING

HDs must be administered safely using protective medical devices and techniques. Examples of protective medical devices include needleless and closed systems. Examples of protective techniques include spiking or priming of IV tubing with a non-HD solution in a C-PEC and crushing tablets in a plastic pouch.

Appropriate PPE must be worn when administering HDs. After use, PPE must be removed and disposed of in a waste container approved for trace-contaminated HD waste at the site of drug administration. Equipment (such as tubing and needles) and packaging materials must be disposed of properly, such as in HD waste containers, after administration.

CSTDs must be used for administration of antineoplastic HDs when the dosage form allows. Techniques and ancillary devices that minimize the risk posed by open systems must be used when administering HDs through certain routes. Administration into certain organs or body cavities (e.g., the bladder, eye, peritoneal cavity, or chest cavity) often requires equipment for which locking connections may not be readily available or possible.

Healthcare personnel should avoid manipulating HDs such as crushing tablets or opening capsules if possible. Liquid formulations are preferred if solid oral dosage forms are not appropriate for the patient. If HD dosage forms do require manipulation such as crushing tablet(s) or opening capsule(s) for a single dose, personnel must don appropriate PPE and use a plastic pouch to contain any dust or particles generated.

15. DEACTIVATING, DECONTAMINATING, CLEANING, AND DISINFECTING

All areas where HDs are handled and all reusable equipment and devices must be deactivated, decontaminated, and cleaned. Additionally, sterile compounding areas and devices must be subsequently disinfected.

The entity must establish written procedures for decontamination, deactivation, and cleaning, and for sterile compounding areas disinfection. Additionally, cleaning of nonsterile compounding areas must comply with <u>(795)</u> and cleaning of sterile compounding areas must comply with <u>(797)</u>. Written procedures for cleaning must include procedures, agents used, dilutions (if used), frequency, and documentation requirer

All personnel who perform deactivation, decontamination, cleaning, and disinfection activities in HD handling areas must be trained in appropriate procedures to protect themselves and the environment from contamination. All personnel performing these activities must wear

appropriate PPE resistant to the cleaning agents used, including two pairs of chemotherapy gloves and impermeable disposable gowns (see *Personal Protective Equipment*). Additionally, eye protection and face shields must be used if splashing is likely. If warranted by the activity, respiratory protection must be used.

The deactivating, decontaminating, cleaning, and disinfecting agents selected must be appropriate for the type of HD contaminant(s), location, and surface materials. The products used must be compatible with the surface material. Consult manufacturer or supplier information for compatibility with cleaning agents used. Agents used for deactivation, decontamination, and cleaning should be applied through the use of wipes wetted with appropriate solution and not delivered by a spray bottle to avoid spreading HD residue. All disposable materials must be discarded to meet EPA regulations and the entity's policies. Perform cleaning in areas that are sufficiently ventilated. <u>Table 5</u> summarizes the purpose and example agents for each step.

Table 5. Cleaning Steps

Cleaning Step Purpose		Example Agents	
Deactivation	Render compound inert or inactive	As listed in the HD labeling or other agents which may incorporate Environmental Protection Agency (EPA)-registered oxidiz- ers (e.g., peroxide formulations, sodium hypochlorite, etc.)	
Decontamination	Remove HD residue	Materials that have been validated to be ef- fective for HD decontamination, or through other materials proven to be effective through testing, which may include alcohol, water, peroxide, or sodium hypochlorite	
Cleaning	Remove organic and inorganic material	Germicidal detergent	
Disinfection (for sterile manipulations)	Destroy microorganisms	EPA-registered disinfectant and/or sterile al- cohol as appropriate for use	

15.1 Deactivation

Deactivation renders a compound inert or inactive. Residue from deactivation must be removed by decontaminating the surface. There is no one proven method for deactivating all compounds. The ultimate goal should be complete surface decontamination. Products that have known deactivation properties (EPA-registered oxidizing agents that are appropriate for the intended use) should be used when possible. Care should be taken when selecting materials for deactivation due to potential adverse effects (hazardous byproducts, respiratory effects, and caustic damage to surfaces). Damage to surfaces is exhibited by corrosion to stainless steel surfaces caused by sodium hypochlorite if left untreated. To prevent corrosion, sodium hypochlorite must be neutralized with sodium thiosulfate or by following with an agent to remove the sodium hypochlorite (e.g., sterile alcohol, sterile water, germicidal detergent, or sporicidal agent).

15.2 Decontamination

Decontamination occurs by inactivating, neutralizing, or physically removing HD residue from non-disposable surfaces and transferring it to absorbent, disposable materials (e.g., wipes, pads, or towels) appropriate to the area being cleaned. When choosing among various products available for decontaminating HDs, consideration should be given to surface compatibility and facility requirements. It is imperative to adhere to manufacturer's use instructions. Because of the growing number of assays available for HDs, additional surface wipe sampling is now possible and should be done to document the effectiveness of any agent used for decontamination of HD residue from work surfaces (see *Environmental Quality and Control*).

The amount of HD containingtion introduced into the C-PEC may be reduced by wiping down HD containers. The solution used for wiping HD packaging must not alter the product label. The work surface of the C-PEC must be decontaminated between compounding of different HDs. The C-PEC must be decontaminated at least daily (when used), any time a spill occurs, before and after certification, any time voluntary interruption occurs, and if the ventilation tool is moved.

C-PECs may have areas under the work tray where contamination can build up. These areas must be deactivated, decontaminated, ar cleaned at least monthly to reduce the contamination level in the C-PEC. Accessing this area may be difficult. Deactivate, decontamination clean as much as possible of the C-PEC surfaces before accessing the area under the work tray. When deactivating, decontaminating, and

cleaning the area under the work tray of a C-PEC, the containment airflows are compromised by opening the cabinets. To provide protection to the worker performing this task, respiratory protection may be required.

15.3 Cleaning

Cleaning is a process that results in the removal of contaminants (e.g., soil, microbial contamination, HD residue) from objects and surfaces using water, detergents, surfactants, solvents, and/or other chemicals. Cleaning agents used on compounding equipment should not introduce microbial contamination. No cleaning step may be performed when compounding activities are occurring.

15.4 Disinfection

Disinfection is a process of inhibiting or destroying microorganisms. Before disinfection can be adequately performed, surfaces must be cleaned. Disinfection must be done for areas intended to be sterile, including the sterile compounding areas.

16. SPILL CONTROL

All personnel who may be required to clean up a spill of HDs must receive proper training in spill management and the use of PPE and NIOSHcertified respirators (see *Personal Protective Equipment*). Spills must be contained and cleaned immediately only by qualified personnel with appropriate PPE. Qualified personnel must be available at all times while HDs are being handled. Signs must be available for restricting access to the spill area. Spill kits containing all of the materials needed to clean HD spills must be readily available in all areas where HDs are routinely handled. If HDs are being prepared or administered in a non-routine healthcare area, a spill kit and respirator must be available. All spill materials must be disposed of as hazardous waste.

The circumstances and management of spills must be documented. Personnel who are potentially exposed during the spill or spill clean up or who have direct skin or eye contact with HDs require immediate evaluation. Non-employees exposed to an HD spill should follow entity policy, which may include reporting to the designated emergency service for initial evaluation and completion of an incident report or exposure form.

SOPs must be developed to prevent spills and to direct the clean up of HD spills. SOPs must address the size and scope of the spill and specify who is responsible for spill management and the type of PPE required. The management of the spill (e.g., decontamination, deactivation, and cleaning) may be dependent on the size and type of spill. The SOP must address the location of spill kits and clean-up materials as well as the capacity of the spill kit. Written procedures should address use of appropriate full-facepiece, chemical cartridge-type respirators if the capacity of the spill kit is exceeded or if there is known or suspected airborne exposure to vapors or gases.

17. DOCUMENTATION AND STANDARD OPERATING PROCEDURES

The entity must maintain SOPs for the safe handling of HDs for all situations in which these HDs are used throughout a facility. The SOPs must be reviewed at least every 12 months by the designated person, and the review must be documented. Revisions in forms or records must be made as needed and communicated to all personnel handling HDs.

The SOPs for handling of HDs should include:

- Hazard communication program
- Occupational safety program
- Designation of HD areas
- Receipt
- Storage
- Compounding
- Use and maintenance of proper engineering controls (e.g., C-PECs, C-SECs, and CSTDs)
- · Hand hygiene and use of PPE based on activity (e.g., receipt, transport, compounding, administration, spill, and disposal)
- · Deactivation, decontamination, cleaning, and disinfection
- Dispensing
- Transport
- Administering
- Environmental monitoring (e.g., wipe sampling)
- Disposal
- Spill control
- Medical surveillance

Personnel who transport, compound, or administer HDs must document their training according to OSHA standards (see OSHA Standard 1910.120 Hazardous Waste Operations and Emergency Response) and other applicable laws and regulations.

18. MEDICAL SURVEILLANCE

Medical surveillance is part of a comprehensive exposure control program complementing engineering controls, safe work processes, and use of PPE. Healthcare workers who handle HDs as a regular part of their job assignment should be enrolled in a medical surveillance program.

The general purpose of surveillance is to minimize adverse health effects in personnel potentially exposed to HDs. Medical surveillance programs involve assessment and documentation of symptom complaints, physical findings, and laboratory values (such as a blood count) to determine whether there is a deviation from the expected norms.

Medical surveillance can also be viewed as a secondary prevention tool that may provide a means of early detection if a health problem develops. Tracking personnel through medical surveillance allows the comparison of health variables over time in individual workers, which may facilitate early detection of a change in a laboratory value or health condition. Medical surveillance programs also look for trends in populations of workers. Examining grouped data compared with data from unexposed workers may reveal a small alteration or increase in the frequency of a health effect that would be obscured if individual workers' results alone were considered.

Medical surveillance evaluates the protection afforded by engineering controls, other administrative controls, safe work processes, PPE, and worker education about the hazards of the materials they work with in the course of their duties. The data-gathering elements of a medical surveillance program are used to establish a baseline of workers' health and then to monitor their future health for any changes that may result from exposure to HDs.

Elements of a medical surveillance program should be consistent with the entity's Human Resource policies and should include:

- Development of an organized approach to identify workers who are potentially exposed to HDs on the basis of their job duties
- Use of an entity-based or contracted employee health service to perform the medical surveillance while protecting the confidentiality of the employees' personal medical information
- Initial baseline assessment (pre-placement) of a worker's health status and medical history. Data elements collected include a medical (including reproductive) history and work history to assess exposure to HDs, physical examination, and laboratory testing. Methods used to assess exposure history include a review of:
 - Records of HDs handled, with quantities and dosage forms
 - Estimated number of HDs handled per week
 - Estimates of hours spent handling HDs per week and/or per month
 - Performance of a physical assessment and laboratory studies linked to target organs of commonly used HDs, such as a baseline complete blood count. Biological monitoring to determine blood or urine levels of specific HDs is not currently recommended in surveillance protocols, but may have a role in the follow-up of acute spills with a specific agent.
- Medical records of surveillance should be maintained according to OSHA regulation concerning access to employee exposure and medical records
- Monitoring workers' health prospectively through periodic surveillance using the elements of data gathering described above (updated health and exposure history, physical assessment, and laboratory measures, if appropriate)
- Monitoring of the data to identify prevention failure leading to health effects; this monitoring may occur in collaboration with the employee health service
- Development of a follow-up plan for workers who have shown health changes suggesting toxicity or who have experienced an acute exposure. This follow-up should include evaluation of current engineering and administrative controls and equipment to ensure that all systems are appropriately and accurately implemented (see *Follow-Up Plan*)
- Completion of an exit examination when a worker's employment at the entity ends, to document the information on the employee's medical, reproductive, and exposure histories. Examination and laboratory evaluation should be guided by the individual's history of exposures and follow the outline of the periodic evaluation

18.1 Follow-Up Plan

The occurrence of exposure-related health changes should prompt immediate re-evaluation of primary preventive measures (e.g., administrative and engineering controls, PPE, and others). In this manner, medical surveillance acts as a check on the effectiveness of controls already in use.

The entity should take the following actions:

- Perform a post-exposure examination tailored to the type of exposure (e.g., spills or needle sticks from syringes containing HDs). An
 assessment of the extent of exposure should be conducted and included in a confidential database and in an incident report. The
 physical examination should focus on the involved area as well as other organ systems commonly affected (i.e., the skin and mucous
 membranes for direct contact or inhalation; the pulmonary system for aerosolized HDs). Treatment and laboratory studies will follow as
 indicated and be guided by emergency protocols
- Compare performance of controls with recommended standards; conduct environmental sampling when analytical methods are available
- Verify and document that all engineering controls are in proper operating condition
- Verify and document that the worker complied with existing policies. Review policies for the use of PPE and employee complianco with PPE use and policies. Review availability of appropriate PPE (see *Personal Protective Equipment*)
- · Develop and document a plan of action that will prevent additional exposure of workers

- Ensure confidential, two-way communication between the worker and the employee health unit(s) regarding notification, discussions about a change in health condition, or detection of an adverse health effect
- · Provide and document a follow-up medical survey to demonstrate that the plan implemented is effective
- Ensure that any exposed worker receives confidential notification of any adverse health effect. Offer alternative duty or temporary reassignment
- · Provide ongoing medical surveillance of all workers at risk for exposure to HDs to determine whether the plan implemented is effective

GLOSSARY

Active pharmaceutical ingredient (API):

Any substance or mixture of substances intended to be used in the compounding of a drug preparation, thereby becoming the active ingredient in that preparation and furnishing pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease in humans and animals or affecting the structure and function of the body.

Alternative duty:

Performance of other tasks that do not include the direct handling of HDs.

Ante-room:

An ISO Class 7 or cleaner room where personnel hand hygiene, garbing procedures, and other activities that generate high particulate levels are performed. The ante-room is the transition room between the unclassified area of the facility and the buffer room.

Assessment of risk:

Evaluation of risk to determine alternative containment strategies and/or work practices.

Beyond-use date (BUD):

The date or time beyond which a compounded preparation cannot not be used and must be discarded (see (795) and (797)). The date or time is determined from the date or time when the preparation was compounded.

Biological safety cabinet (BSC):

A ventilated cabinet often used for preparation of hazardous drugs. These cabinets are divided into three general classes (Class I, Class II, and Class III). Class II BSCs are further divided into types (Type A1, Type A2, Type B1, and Type B2). See <u>Appendix 3</u> for details.

Buffer room:

A type of C-SEC under negative pressure that meets ISO Class 7 or better air quality where the C-PEC that generates and maintains an ISO Class 5 environment is physically located. Activities that occur in this area are limited to the preparation and staging of components and supplies used when compounding HDs.

Chemotherapy glove:

A medical glove that meets the ASTM Standard Practice for Assessment of Resistance of Medical Gloves to Permeation by Chemotherapy Drugs (D6978) or its successor.

Classified space:

An area that maintains an air cleanliness classification based on the International Organization for Standardization (ISO).

Cleaning:

The process of removing soil (e.g., organic and inorganic material) from objects and surfaces, normally accomplished by manually or mechanically using water with detergents or enzymatic products.

Closed-system drug-transfer device (CSTD):

A drug-transfer device that mechanically prohibits the transfer of environmental contaminants into the system and the escape of HD or vapor concentrations outside the system.

Compounded preparation:

A nonsterile or sterile drug or nutrient preparation that is compounded in a licensed pharmacy or other healthcare-related facility in response to or anticipation of a prescription or a medication order from a licensed prescriber.

Compounding aseptic containment isolator (CACI):

A specific type of CAI that is designed for the compounding of sterile HDs. The CACI is designed to provide worker protection from exposure to undesirable levels of airborne drugs throughout the compounding and material transfer processes and to provide an aseptic environment with unidirectional airflow for compounding sterile preparations.

Compounding aseptic isolator (CAI):

An isolator specifically designed for compounding sterile, non-hazardous pharmaceutical ingredients or preparations. The CAI is designed to maintain an aseptic compounding environment throughout the compounding and material transfer processes.

Compounding personnel:

Individuals who participate in the compounding process.

Containment primary engineering control (C-PEC):

A ventilated device designed and operated to minimize worker and environmental exposures to HDs by controlling emissions of airborne contaminants through the following:

- · The full or partial enclosure of a potential contaminant source
- · The use of airflow capture velocities to trap and remove airborne contaminants near their point of generation
- · The use of air pressure relationships that define the direction of airflow into the cabinet
- The use of HEPA filtration on all potentially contaminated exhaust streams

Containment secondary engineering control (C-SEC):

The room with fixed walls in which the C-PEC is placed. It incorporates specific design and operational parameters required to contain the potential hazard within the compounding room.

Containment segregated compounding area (C-SCA):

A type of C-SEC with nominal requirements for airflow and room pressurization as they pertain to HD compounding.

Containment ventilated enclosure (CVE):

A full or partial enclosure that uses ventilation principles to capture, contain, and remove airborne contaminants through HEPA filtration and prevent their release into the work environment.

Deactivation:

Treatment of an HD contaminant on surfaces with a chemical, heat, ultraviolet light, or another agent to transform the HD into a less hazardous agent.

Decontamination:

Inactivation, neutralization, or removal of HD contaminants on surfaces, usually by chemical means.

Doff:

To remove PPE.

Don:

To put on PPE.

Disinfection:

The process of inhibiting or destroying microorganisms.

Engineering control:

Primary, secondary, and supplemental devices designed to eliminate or reduce worker exposure to HDs.

EPA-registered disinfectant:

Antimicrobial products registered with the Environmental Protection Agency (EPA) for healthcare use against pathogens specified in the

product labeling.

Externally vented:

Exhausted to the outside.

Final dosage form:

Any form of a medication that requires no further manipulation before administration.

Globally Harmonized System of Classification and Labeling of Chemicals (GHS):

A system for standardizing and harmonizing the classification and labeling of chemicals.

Goggles:

Tight-fitting eye protection that completely covers the eyes, eye sockets, and facial area that immediately surrounds the eyes. Goggles provide protection from impact, dust, and splashes. Some goggles fit over corrective lenses.

Hazardous drug (HD):

Any drug identified by at least one of the following criteria:

- · Carcinogenicity, teratogenicity, or developmental toxicity
- · Reproductive toxicity in humans
- · Organ toxicity at low dose in humans or animals
- · Genotoxicity or new drugs that mimic existing HDs in structure or toxicity

High-efficiency particulate air (HEPA) filtration:

An extended-medium, dry-type filter in a rigid frame, having a minimum particle collection efficiency of 99.97% for particles with a mass median diameter of 0.3 µm when tested at a rated airflow in accordance with MIL STD 282 using IEST Recommended Standard RP-CC001.5.

Negative-pressure room:

A room that is maintained at a lower pressure than the adjacent areas; therefore the net flow of air is into the room.

Pass-through:

An enclosure with interlocking doors that is positioned between two spaces for the purpose of reducing particulate transfer while moving materials from one space to another. A pass-through serving negative-pressure rooms needs to be equipped with sealed doors.

Personal protective equipment (PPE):

Items such as gloves, gowns, respirators, goggles, faceshields, and others that protect individual workers from hazardous physical or cl exposures.

Positive-pressure room:

A room that is maintained at a higher pressure than the adjacent areas; therefore, the net flow of air is out of the room.

Repackaging:

The act of removing a product from its original primary container and placing it into another primary container, usually of smaller size.

Safety data sheet (SDS):

An informational document that provides written or printed material concerning a hazardous chemical. The SDS is prepared in accordance with the HCS [previously known as a Material Safety Data Sheet (MSDS)].

Spill kit:

A container of supplies, warning signage, and related materials used to contain the spill of an HD.

Standard operating procedure (SOP):

Written procedures describing operations, testing, sampling, interpretation of results, and corrective actions that relate to the operations that are taking place.

Supplemental engineering control:

An adjunct control (e.g., CSTD) that may be used concurrently with primary and secondary engineering controls. Supplemental engineering controls offer additional levels of protection and may facilitate enhanced occupational protection, especially when handling HDs outside of primary and secondary engineering controls (e.g., during administering).

Unclassified space:


A space not required to meet any air cleanliness classification based on the International Organization for Standardization (ISO).

APPENDICES

Appendix 1: Acronyms

АСРН	Air changes per hour	
API	Active pharmaceutical ingredient	
ASTM	American Society for Testing and Materials	
BSC	Biological safety cabinet	
BUD	Beyond-use date	
CACI	Compounding aseptic containment isolator	
CAI	Compounding aseptic isolator	
CDC	Centers for Disease Control and Prevention	
C-PEC	Containment primary engineering control	
C-SCA	Containment segregated compounding area	
C-SEC	Containment secondary engineering control	
CSP	Compounded sterile preparation	
CSTD	Closed-system drug-transfer device	
CVE	Containment ventilated enclosure	
EPA	Environmental Protection Agency	
GHS	Globally Harmonized System of Classification and Labeling of Chemicals	
HCS	Hazard Communication Standard	

HD	Hazardous drug	
НЕРА	High-efficiency particulate air	
IV	Intravenous	
LAFW	Laminar airflow workbench	
NIOSH	National Institute for Occupational Safety and Health	
ONS	Oncology Nursing Society	
OSHA	Occupational Safety and Health Administration	
PAPR	Powered air-purified respirator	
PPE	Personal protective equipment	
SDS	Safety Data Sheet	
SOP	Standard operating procedure	
ULPA	Ultra-low particulate air	
UPS	Uninterrupted power source	



Appendix 2: Examples of Designs for Hazardous Drug Compounding Areas^a

^a The arrows indicate direction of airflow.

Appendix 3: Types of Biological Safety Cabinets

Class I: A BSC that protects personnel and the environment but does not protect the product/preparation. A minimum velocity of 75 linear feet/minute of unfiltered room air is drawn through the front opening and across the work surface, providing personnel protection. The air is then passed through a HEPA/ULPA (ultra-low particulate air) filter, either into the room or to the outside in the exhaust plenum, providing environmental protection.

Class II: Class II (Types A1, A2, B1, and B2) BSCs are partial barrier systems that rely on the movement of air to provide personnel, environmental, and product/preparation protection. Personnel and product/preparation protection are provided by the combination of inward and downward airflow captured by the front grille of the cabinet. Side-to-side cross-contamination of products/preparations is minimized by the internal downward flow of HEPA/ULPA filtered air moving toward the work surface and then drawn into the front and rear intake grilles. Environmental protection is provided when the cabinet exhaust air is passed through a HEPA/ULPA filter.

Type A1 (formerly, Type A): These Class II BSCs maintain a minimum inflow velocity of 75 feet/minute; have HEPA-filtered, down-flow air that is a portion of the mixed down-flow and inflow air from a common plenum; may exhaust HEPA-filtered air back into the laboratory or to the environment through an exhaust canopy; and may have positive-pressure contaminated ducts and plenums that are not surrounded by negative-pressure plenums. Type A1 BSCs are not suitable for use with volatile toxic chemicals and volatile radionuclides.

Type A2 (formerly, Type B3): These Class II BSCs maintain a minimum inflow velocity of 100 feet/minute; have HEPA-filtered, down-flow air that is a portion of the mixed down-flow and inflow air from a common exhaust plenum; may exhaust HEPA-filtered air back into the laboratory or to the environment through an exhaust canopy; and have all contaminated ducts and plenums under negative pressure or surrounded by negative-pressure ducts and plenums. If these cabinets are used for minute quantities of volatile toxic chemicals and trace amounts of radionuclides, they must be exhausted through properly functioning exhaust canopies.

Type B1: These Class II BSCs maintain a minimum inflow velocity of 100 feet/minute; have HEPA-filtered, down-flow air composed largely of uncontaminated, recirculated inflow air; exhaust most of the contaminated down-flow air through a dedicated duct exhausted to the atmosphere after passing it through a HEPA filter; and have all contaminated ducts and plenums under negative pressure or surrounded by negative-pressure ducts and plenums. If these cabinets are used for work involving minute quantities of volatile toxic chemicals and trace amounts of radionuclides, the work must be done in the directly exhausted portion of the cabinet.

Type B2 (total exhaust): These Class II BSCs maintain a minimum inflow velocity of 100 feet/minute; have HEPA-filtered, down-flow air drawn from the laboratory or the outside; exhaust all inflow and down-flow air to the atmosphere after filtration through a HEPA filter without recirculation inside the cabinet or return to the laboratory; and have all contaminated ducts and plenums under negative pressure or surrounded by directly exhausted negative-pressure ducts and plenums. These cabinets may be used with volatile toxic chemicals and radionuclides.

Class III: The Class III BSC is designed for work with highly infectious microbiological agents and other hazardous operations. It provides maximum protection for the environment and the worker. It is a gas-tight enclosure with a viewing window that is secured with locks and/or requires the use of tools to open. Both supply and exhaust air are HEPA/ULPA filtered. Exhaust air must pass through two HEPA/ULPA filters in series before discharge to the outdoors.

REFERENCES

- 1. American College of Occupational and Environmental Medicine: ACOEM Task Force on Reproductive Toxicology. Reproductive and developmental hazard management guidance. April 26, 2011.
- 2. American Society of Clinical Oncology. Worker safety when handling hazardous drugs is focus of statement by oncology societies. March 3, 2015.
- American Society of Health-System Pharmacists. ASHP guidelines on compounding sterile preparations. Am J Health-Syst Pharm. 2014;71(2):145–166.
- 4. American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. *Am J Health-Syst Pharm*. 2006; 63:1172–1193.
- 5. Baker EL, editor. Surveillance in occupational health and safety. Am J Public Health. 1989;79(Suppl.):1-63.
- Chaffee BW, Armitstead JA, Benjamin BE, Cotugno MC, Forrey RA, Hintzen BL, et al. Guidelines for the safe handling of hazardous drugs: consensus recommendations. *Am J Health-Syst Pharm.* 2010;67(18):1545–1546.
- 7. Connor TH. Permeability of nitrile rubber, latex, polyurethane, and neoprene gloves to 18 antineoplastic drugs. *Am J Health-Syst Pharm*. 1999;56(23):2450–2453.
- 8. Connor TH, Mackenzie BA, DeBord DG. Clarification about hazardous drugs. Am J Health-Syst Pharm. 2012;69(22):1949–1950.
- 9. Controlled Environment Testing Association. CETA application guide for informational notes to meet the NSF/ANSI 49:2010a sta requirements CAG-010-2011. July 1, 2011. Raleigh, NC: CETA; 2011.

- 10. Controlled Environment Testing Association. CETA application guide for the use of surface decontaminants in biosafety cabinets CAG-004-2007. January 30, 2007. Raleigh, NC:ETA;2007.
- 11. Controlled Environment Testing Association. CETA compounding isolator testing guide, CAG-002-2006. Revised December 8, 2008.Raleigh, NC: CETA; 2008.
- 12. Controlled Environment Testing Association. CETA CAG-005-2007 servicing hazardous drug compounding primary engineering controls. Raleigh, NC: CETA; 2007.
- Centers for Disease Control and Prevention. Biosafety in microbiological and biomedical laboratories (BMBL) 5th edition. Page last updated: March 13, 2015. Atlanta, GA: CDC, 2015. <u>http://www.cdc.gov/biosafety/publications/bmbl5</u>.
- 14. Centers for Disease Control and Prevention. Workplace safety and health: *Chemotherapy drug exposures at an oncology clinic—Florida*. June 2012. Atlanta, GA: CDC; 2012 <u>http://www.cdc.gov/niosh/hhe/reports/pdfs/2009-0148-3158.pdf</u>.
- Centers for Disease Control and Prevention. Hand hygiene in healthcare settings. Page last updated: May 1, 2015. Atlanta, GA: CDC; 2015. <u>http://www.cdc.gov/handhygiene/</u>.
- 16. Centers for Disease Control and Prevention. NIOSH Alert: preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings Cincinnati, OH: Department of Health and Human Services, CDC; 2004.
- 17. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings, 2014 Cincinnati, OH: Department of Health and Human Services, CDC; 2014.
- Centers for Disease Control and Prevention. The National Personal Protective Technology Laboratory (NPPTL). Respirator trusted-source information. Section 3: ancillary respirator information. Atlanta, GA: CDC; 2014. <u>http://www.cdc.gov/niosh/npptl/topics/respirators/disp_part/respsource3.html</u>.
- 19. Centers for Disease Control and Prevention. Workplace solutions: medical surveillance for healthcare workers exposed to hazardous drugs. Department of Health and Human Services, CDC; 2012.
- 20. Centers for Disease Control and Prevention. Workplace solutions: personal protective equipment for health care workers who work with hazardous drugs. Cincinnati, OH: Department of Health and Human Services, CDC; 2009.
- 21. Centers for Disease Control and Prevention. Workplace solutions: safe handling of hazardous drugs for veterinary healthcare workers. Cincinnati, OH: Department of Health and Human Services, CDC; 2010.
- 22. Goodin S, Griffith N, Chen B, Chuk K, Daouphars M, Doreau C, et al. Safe handling of oral chemotherapeutic agents in clinical practice: recommendations from an international pharmacy panel. *J Oncol Pract.* 2011;7(1):7–12.
- 23. Hematology/Oncology Pharmacy Association. Ensuring healthcare worker safety when handling hazardous drugs: the joint position statement from the Oncology Nursing Society, the American Society of Clinical Oncology, and the Hematology/Oncology Pharmacy Association. 2015. <u>http://www.hoparx.org/uploads/HOPA_ASCO_ONS_Joint_Position.pdf</u>
- 24. International Society of Oncology Pharmacy Practitioners Standards Committee. ISOPP standards of practice. Safe handling of cytotoxics. *J Oncol Pharm Pract.* 2007;13 Suppl:1–81.
- 25. Massoomi F. The evolution of the CSTD. Oncology Safety 2015;12(2 suppl).
- 26. McDiarmid MA, Emmett EA. Biological monitoring and medical surveillance of workers exposed to antineoplastic agents. *Semin Occup Med.* 1987;2(2):109–117.
- 27. NST International. NSF/ANSI 49-2011. Biosafety cabinetry: design, construction, performance, and field certification. Annex E. 2011.
- Neuss MN, Polovich M, McNiff K, Esper P, Gilmore TR, LeFebvre KB, et al. 2013 updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards including standards for the safe administration and management of oral chemotherapy, Oncol Nursing Forum. 2013;40(3):225–233.
- 29. Oncology Nursing Society. Safe handling of hazardous drugs. In: Polovich M, editor. 2nd ed. Pittsburgh, PA: Oncology Nursing Society; 2011.
- 30. Oncology Nursing Society, American Society of Clinical Oncology, and Hematology/Oncology Pharmacy Association. Joint position statement: ensuring healthcare worker safety when handling hazardous drugs. 2015. <u>https://www.ons.org/advocacy-policy/positions/practice/hazardous-drugs</u>
- 31. Occupational Safety and Health Administration, The Joint Commission, and NIOSH letter to hospitals, April 4, 2011. Washington, DC: United States Department of Labor. <u>http://www.osha.gov/ooc/drug-letter.pdf</u>.
- 32. Occupational Safety and Health Administration. Hospital respiratory protection program toolkit. OSHA publication number 3767-05 2015.
- Occupational Safety and Health Administration. Occupational Safety and Health Standards: hazard communication. Washington, DC: United States Department of Labor; 2012. <u>http://www.osha.gov/dsg/hazcom/standards.html</u>.
- 34. Occupational Safety and Health Administration. Occupational Safety and Health Standards: access to employee exposure and medical records [29 CFR 1910.1020]. Washington, DC: United States Department of Labor.
- 35. Occupational Safety and Health Administration. Occupational Safety and Health Standards: hazardous waste operations and em y response [29 CFR 1910.120]. Washington, DC: United States Department of Labor.
- 36. OSHA Technical Manual Controlling occupational exposure to hazardous drugs. Section VI, Chapter 2. Washington, DC: United States Department of Labor;1999.

- 37. Occupational Safety and Health Administration. Personal protective equipment. Washington, DC: United States Department of Labor; 2003.
- 38. Occupational Safety and Health Administration. *Respiratory protection eTool* [29 CFR 1910.134]. Washington, DC: United States Department of Labor.
- 39. Occupational Safety and Health Administration. Occupational Safety and Health Standards: toxic and hazardous substances [CFR 1910.1200]. Washington, DC: United States Department of Labor; 2013. <u>https://www.osha.gov/SLTC/hazardoustoxicsubstances/index.html</u>
- 40. Power LA. Closed-system transfer devices for safe handling of injectable hazardous drugs. *Pharm Pract News*. New York: McMahon Publishing Group; June 2013;1-16.
- 41. Power LA, Sessink PJM, Gesy K, Charbonneau F. Hazardous drug residue on exterior vial surfaces: evaluation of a commercial manufacturing process. *Hosp Pharm.* 2014;49(4):355–362.
- 42. Sessink PJM, Trahan J, Coyne JW. Reduction in surface contamination with cyclophosphamide in 30 US hospital pharmacies following implementation of a closed-system drug transfer device. *Hosp Pharm.* 2013;48(3):204–212.
- 43. University HealthSystem Consortium. UHC consensus statement: model hazardous drug safety plan for institutions. Chicago, IL: UHC; October 2009, revised January 2011.
- 44. Watts D. Gloves as PPE: standards for permeation and penetration. Clean Air Containment Rev. Issue 2; April 2010:16-20.
- 45. Wesdock JC, Sokas RK. Medical surveillance in work-site safety and health programs. Am Fam Physician. 2000;61(9):2785–2790.

Auxiliary Information - Please check for your question in the FAQs before contacting USP.

Topic/Question	Contact	Contact		
<800> HAZARDOUS DRUGS - H/ HEALTHCARE SETTINGS	ANDLING IN <u>Brian Serumaga</u> Science Program		CMP2020 Compou	nding 2020

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. 41(2)

Page Information:

USP43-NF38 - 7071 USP42-NF37 - 7002 USP41-NF36 2S - 9212

Current DocID: GUID-5D76173F-5CB6-47B8-815E-7C275A916085_7_en-US DOI: <u>https://doi.org/10.31003/USPNF_M7808_07_01</u> DOI ref: <u>ifp62</u>